¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"adrenergic neuron blocking agent"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • association neuron
    ¿¬ÇսŰ漼Æ÷
  • autonomic neuron
    ÀÚÀ²½Å°æ¼¼Æ÷
  • alpha motor neuron
    ¾ËÆÄ¿îµ¿½Å°æ¼¼Æ÷
  • bipolar neuron
    µÎ±Ø½Å°æ¼¼Æ÷
  • commissural neuron
    ¸Â±³Â÷½Å°æ¼¼Æ÷
  • cholinergic neuron
    Äݸ°½Å°æ¼¼Æ÷
  • dopaminergic neuron
    µµÆÄ¹Î½Å°æ¼¼Æ÷
  • efferent neuron
    ³¯½Å°æ¼¼Æ÷, ¿ø½É½Å°æ¼¼Æ÷
  • enteric neuron
    âÀڽŰ漼Æ÷, Àå½Å°æ¼¼Æ÷
  • first-order neuron
    ÀÏÂ÷½Å°æ¼¼Æ÷, ÀÏÂ÷½Å°æ¿ø
  • Golgi type I neuron
    ±äÃà»è½Å°æ¼¼Æ÷, °ñÁö1Çü½Å°æ¼¼Æ÷
  • Golgi type II neuron
    ªÀºÃà»è½Å°æ¼¼Æ÷, °ñÁö2Çü½Å°æ¼¼Æ÷
  • horizontal neuron
    ¼öÆò½Å°æ¼¼Æ÷
  • intercalated neuron
    »çÀ̽Ű漼Æ÷, °³Àç´º·±
  • internuncial neuron
    »çÀ̽Ű漼Æ÷, °³Àç´º·±
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antimetabolic agent
    Ç×´ë»ç¹°Áú
  • antitumor agent
    Ç×¾ÏÁ¦
  • etiologic agent
    ¿øÀÎü, º´ÀÎü
  • hyperosmotic agent
    °í»ïÅõ¾ÐÁ¦
  • induction agent
    À¯µµ¹°Áú
  • infectious agent
    °¨¿°Ã¼, °¨¿°¿ø
  • oxidizing agent
    »êÈ­Á¦
  • pressor agent
    ½Â¾ÐÁ¦, Ç÷¾Ð»ó½ÂÁ¦
  • sclerosing agent
    °æÈ­Á¦
  • tocolytic agent
    ÀڱüöÃà¾ïÁ¦Á¦
  • toxic agent
    µ¶¹°, µ¶±Ø¹°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • depolarizing neuromuscular blocking drug
    Å»ºÐ±Ø½Å°æ±ÙÂ÷´ÜÁ¦
  • ganglionic blocking drug
    ½Å°æÀýÂ÷´Ü¾àÁ¦
  • alpha motor neuron
    ¾ËÆÄ¿îµ¿½Å°æ¼¼Æ÷
  • association neuron
    ¿¬ÇսŰ漼Æ÷
  • autonomic neuron
    ÀÚÀ²½Å°æ¼¼Æ÷
  • bipolar neuron
    µÎ±Ø½Å°æ¼¼Æ÷
  • cholinergic neuron
    Äݸ°¼º½Å°æ¼¼Æ÷
  • commissural neuron
    ¸Â±³Â÷½Å°æ¼¼Æ÷
  • dopaminergic neuron
    µµÆÄ¹Î½Å°æ¼¼Æ÷
  • motor neuron disease
    ¿îµ¿½Å°æ¼¼Æ÷º´
  • motor neuron disorder
    ¿îµ¿½Å°æ¼¼Æ÷Àå¾Ö
  • efferent neuron
    ³¯½Å°æ¼¼Æ÷, ¿ø½É½Å°æ¼¼Æ÷
  • enteric neuron
    âÀڽŰ漼Æ÷
  • first-order neuron
    ÀÏÂ÷½Å°æ¼¼Æ÷
  • Golgi type I neuron
    ±äÃà»è½Å°æ¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • ganglionic blocking action
    ½Å°æÀýÂ÷´ÜÀÛ¿ë.
  • genetic blocking
    À¯ÀüÀû Â÷´Ü(ë¶îîîÜó´Ó¨).
  • genetic blocking
    À¯ÀüÀû Â÷´Ü.
  • golgi type i neuron
    ±äÃà»è½Å°æ¼¼Æ÷
  • golgi type ii neuron
    ªÀºÃà»è½Å°æ¼¼Æ÷
  • horizontal neuron
    ¼öÆò¼¼Æ÷
  • pigment neuron
    »ö¼Ò½Å°æ¼¼Æ÷
  • piriform neuron layer [purkinjes layer]
    Á¶·Õ¹ÚÃþ
  • postganglionic neuron
    (½Å°æ)[ÇØºÎ]ÀýÈÄ´º¿ì·Ð.
  • postsynaptic neuron
    ½Ã³³½ºÈÄ´º·Ð.
  • preganglionic neuron
    (½Å°æ)ÀýÀü´º¿ì·Ð.
  • primary (pain) neuron
    ÀÏÂ÷(Åë)´º¿ì·Ð.
  • primary (pain) neuron
    ÀÏÂ÷(Åë)´º¿ì·Ð.
  • projection neuron
    Åõ»ç½Å°æ¿ø.
  • propriospinal neuron
    °íÀ¯Ã´¼ö´º¿ì·Ð.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • ganglionic blocking agent
    ½Å°æÀýÂ÷´ÜÁ¦.
  • neuromuscular blocking agent
    ½Å°æ±ÙÂ÷´Ü<ºÀ¼â>Á¦(¾à).
  • neuromuscular blocking agent
    ½Å°æ±ÙÂ÷´ÜÁ¦, ½Å°æ±ÙÂ÷´Ü¾à(~ó´Ó¨å·).
  • receptor blocking agent
    ¼ö¿ëüÂ÷´Ü<ºÀ¼â>Á¦.
  • sympathetic blocking agent
    ±³°¨½Å°æÂ÷´Ü<ºÀ¼â>Á¦.
  • adrenergic
    ¾Æµå·¹³¯¸°¼º, ¾Æµå·¹³¯¸°ÀÛµ¿¼º, ¾Æµå·¹³¯¸°(¼º)¾à.
  • adrenergic agonist
    ¾Æµå·¹³¯¸°¼ºÃËÁøÁ¦
  • adrenergic antagonist
    ¾Æµå·¹³¯¸° ±æÇ×¹°Áú
  • adrenergic antagonist
    ¾Æµå·¹³¯¸°¼º ±æÇ×Á¦
  • adrenergic fiber
    ¾Æµå·¹³¯¸°¼º ¼¶À¯
  • adrenergic neurotransmitter
    ¾Æµå·¹³¯¸°¼º ½Å°æÀü´Þ¹°Áú
  • adrenergic receptor
    ¾Æµå·¹³¯¸°¼º ¼ö¿ëü(¼ö¿ë±â, °¨¼ö±â,°¨¼öü)
  • adrenergic stimulating drug
    ¾Æµå·¹³¯¸°ÈïºÐ¾à, ¾Æµå·¹³¯¸°ÀÚ±ØÁ¦.
  • adrenergic stimulating drug
    ¾Æµå·¹³¯¸°(¼º)ÈïºÐ¾à, ¾Æµå·¹³¯¸°(¼º)ÀÚ±ØÁ¦.
  • adrenergic tone
    ¾Æµå·¹³¯¸°¼º ±äÀåµµ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Small pyramidal neuron
    ÀÛÀºÇǶó¹Ô¼¼Æ÷
    [¿¾ ¿ë¾î] ¼ÒÃßü½Å°æ¼¼Æ÷
  • Piriform neuron layer [Purkinje`s layer]
    Á¶·Õ¹ÚÃþ
    [¿¾ ¿ë¾î] Á¶·Õ¹ÚÃþ
  • Medium-sized pyramidal neuron
    Áõ°£ÇǶó¹Ô¼¼Æ÷
    [¿¾ ¿ë¾î] Áß°£Ãßü¼¼Æ÷
  • Large pyramidal neuron
    Å«ÇǶó¹Ô¼¼Æ÷
    [¿¾ ¿ë¾î] ´ëÃßü½Å°æ¼¼Æ÷
  • Unipolar neuron
    Ȭ±Ø½Å°æ¼¼Æ÷
    [¿¾ ¿ë¾î] ´Ü±Ø½Å°æ¿ø
  • Golgi type I neuron
    ±äÃà»è½Å°æ¼¼Æ÷
    [¿¾ ¿ë¾î] ÀåÃà»è´Ù±Ø½Å°æ¿ø
  • Pigment neuron
    »ö¼Ò½Å°æ¼¼Æ÷
    [¿¾ ¿ë¾î] »ö¼Ò½Å°æ¿ø
  • Medium-sized fusiform neuron
    Áß°£¹æÃß¼¼Æ÷
    [¿¾ ¿ë¾î] Áß°£¹æÃß¼¼Æ÷
  • Golgi type II neuron
    ªÀºÃà»è½Å°æ¼¼Æ÷
    [¿¾ ¿ë¾î] ´ÜÃà»è´Ù±Ø½Å°æ¿ø
  • Secretory neuron
    ºÐºñ½Å°æ¼¼Æ÷
    [¿¾ ¿ë¾î] ºÐºñ½Å°æ¿ø
  • Nerve cell [Neuron]
    ½Å°æ¼¼Æ÷ [½Å°æ´ÜÀ§]
    [¿¾ ¿ë¾î] ½Å°æ¼¼Æ÷
  • Neuron
    ½Å°æ¼¼Æ÷ [½Å°æ´ÜÀ§]
    [¿¾ ¿ë¾î] ½Å°æ¼¼Æ÷
  • Neuron
    ½Å°æ¼¼Æ÷ [½Å°æ´ÜÀ§]
    [¿¾ ¿ë¾î] ½Å°æ¿ø
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antiviral agent
    Ç×(ù÷) ¹ÙÀÌ·¯½ºÁ¦(ð¥)
  • bactericidal agent
    »ì±ÕÁ¦(߯жð¥)
  • bacteriostatic agent
    Á¤±ÕÁ¦(ð¡Ð¶ð¤)
  • chaotropic agent
    ¹«Áú¼­À¯¹ßÁ¦(Ùíòñßíë¯Û¡ð¥)
  • chelating agent
    ų·¹ÀÌÆ®Á¦(ð¥)
  • chemotherapeutic agent
    È­Çпä¹ýÁ¦(ûùùÊÖûÛöð¥)
  • cytostatic agent
    ¼¼Æ÷Áõ½Ä¾ïÁ¦Á¦(á¬øàñòãÖåäð¤ð¥)
  • denaturing agent
    º¯¼ºÁ¦(ܨàõð¥)
  • eluting agent
    ¿ë¸®Á¦(éÁ×îð¥)
  • emulsifying agent
    ¿¡¸ÖÁ¯È­Á¦(ûùð¥)
  • F agent
    F Á¦(ð¥)
  • fusogenic agent
    À¶ÇÕ »ý¼ºÁ¦(ë×ùêßæà÷ð¥)
  • germicidal agent
    »ì±ÕÁ¦(߯жð¥)
  • immunosuppressive agent
    ¸é¿ª¾ï¾ÐÁ¦(Øóæ¹åääâð¥)
  • lipotropic agent
    ÁöÁúµ¿¿øÁ¦(ò·òõÔÑê¬ð¥)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • paramagnetic agent
    »óÀÚ¼ºÁ¦Àç
  • protective agent
    º¸È£¾à, ÇÇÆ÷¾à
  • radioopaque agent
    ¹æ»ç¼±ºñÅõ°ú¼ºÁ¦Àç
  • radioprotective agent
    ¹æ»ç¼±¹æÈ£Á¦
  • sclerosing agent
    °æÈ­¾à
  • therapeutic agent
    Ä¡·á¾à
  • thrombolytic agent
    Ç÷Àü¿ëÇØ¾à
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
BA Bachelor of Arts; backache; bacterial agglutination; basilar artery; basion; benzyladenine; best amp...
ADRA1C alpha-1C-adrenergic receptor
ADRBK beta-1-adrenergic receptor kinase
ADRBR adrenergic beta-receptor
ARB adrenergic receptor binder
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
NMB neuromuscular blocking
a Agent
CAA Chicken anaemia agent
FWA fluorescent whitening agent
SMA Snow Mountain Agent
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • alpha adrenergic antagonist
    ¾ËÆÄ ¾Æµå·¹³¯¸° ±æÇ×Á¦
  • alpha-adrenergic receptor
    ¾ËÆÄ-¾Æµå·¹³¯¸° ¼ö¿ëü
  • ¥â-adrenergic

    ¥â-adrenergic agent (

    ¥â-adrenergic receptor blocking agent (º£Å¸ ¾Æµå·¹³¯¸°¼º ¼ö¿ëü Â÷´ÜÁ¦

  • blocking
    Â÷´Ü, ºÀ¼â, Â÷´Ü¾à, ºÀ¼â¾à, Á¡Âø
    1. ±¸½É¼º ½Å°æ·ÎÀÇ Â÷´Ü, ¿¹ÄÁµ¥ ÄÚÄÉÀÎ ÁÖ»ç·Î ÀÎÇÑ Â÷´Ü. ¼¼Æ÷³» »ýÇÕ¼º °úÁ¤ÀÇ ÀúÁö. 2. ¾î¶² ÄÞÇ÷º½º¿¡ ºÎµúÃÆÀ» ¶§ °©ÀÛ½º·± ¿¬»óÀÇ Á¤Áö¿¡ ´ëÇÑ ÇÁ·ÎÀ̵åÇÐÆÄÀÇ ¿ë¾î. 3. ¼¿·ÎÀ̵òÀ¸·Î ħÅõ½ÃŲ Á¶Á÷ Ç¥º»À» ¸ñÆíÀ̳ª ±âŸ ´Ù¸¥ Àû´çÇÑ ¹°Áú·Î °íÁ¤½ÃÄÑ ¸¶ÀÌÅ©·ÎÅè¿¡ ºÎÂø½Ãų ¼ö ÀÖ°Ô ÇÏ´Â °Í.
  • blocking antibody
    Â÷´Ü Ç×ü
    µ¿ÀǾî=blocker.
  • blocking effect
    Â÷´Ü È¿°ú
  • blocking of thought
    »ç°íÀúÇØ
    Á¤½ÅºÐ¿­Áõ¿¡¼­ º¼ ¼ö ÀÖ´Â °ÍÀ¸·Î¼­ ȯÀÚÀÇ È£¼Ò´ë·Î »ç°íÀÇ ±æÀÌ ¸·Çô¼­ ÀÚ½ÅÀ» Ç¥ÇöÇÏ´Â °ÍÀÌ ¾î·Á¿î Á¤½Å »óÅÂ.
  • calcium channel blocking drug
    Ä®½· Åë·Î ºÀ¼â ¾à¹°, Ä®½· Åë·Î Â÷´Ü ¾à¹°
  • depolarizing neuromuscular blocking drug
    Å»ºÐ±Ø¼º ½Å°æ±Ù ºÀ¼â ¾à¹°
  • nerve blocking
    ½Å°æ Â÷´Ü, ½Å°æ Â÷´Ü¹ý
  • alpha efferent motor neuron
    ¾ËÆÄ ¿ø½É ¿îµ¿ ´º¿ì·±, ¾ËÆÄ ¿ø½É¼º ¿îµ¿ ´º·±
  • amputation neuron
    Àý´Ü ½Å°æÁõ
    ¿Ü»ó¼º ½Å°æÁõÀ̶ó°íµµ ÇÏ¸ç ¿Ü»ó ÈÄ¿¡ ¾ß±âµÇ´Â ½Å°æ¼¶À¯ÀÇ µ¢¾î¸® ¸ð¾çÀÇ °úÀ× Àç»ýÀ¸·Î ÁøÁ¤ÇÑ ÀǹÌÀÇ Á¾¾çÀº ¾Æ´Ï´Ù. »óÇÏ¾Ç ¾îµð¼­³ª ¹ß»ýµÇÁö¸¸ ÇÏ¾Ç À̰øºÎ¿¡¼­ È£¹ßÇÑ´Ù. ¹ßÄ¡ ÈÄ¿¡ ¶Ç´Â °ñÀýÀ̳ª ¼ö¼ú ÈÄ¿¡ Àß ¹ß»ýµÇ¸ç ÀÇÄ¡ »ó¿¬ÀÇ ¾Ð¹ÚÀ¸·Î ÇÏ¾Ç À̰øºÎ¿¡¼­ ¹ß»ýµÇ±âµµ ÇÑ´Ù. ÇϼøÀ̳ª Çô¿¡¼­ ¹ß»ýµÇ´Â °æ¿ìµµ ÀÖ´Ù. Å©±â´Â Á÷°æÀÌ 1cm ³»¿ÜÀÌ¸ç ¾ÐÅëÀ̳ª Áö°¢ ÀÌ»óÀ» º¸À̰í Á¶Á÷ÇÐÀûÀ¸·Î ½Å°æ ¼¶À¯°¡ °áÀý¼ºÀ¸·Î Áõ½ÄÇÑ´Ù.
  • anterior motor neuron
    Àü¹æ ¿îµ¿ ´º·±
  • biogenic amine-containing neuron
    »ýü³» ¾Æ¹Î ÇÔÀ¯ ´º¿ì·±
  • bipolar neuron
    µÎ±Ù½Å°æ¿ø
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
Rh blocking test A test for nonagglutinating Rh antibodies: an Rh agglutination test is first carried out; if the test for Rh agglutinins is negative, then 1 drop of anti-Rho agglutinating serum of moderate titre is mixed with the patient's serum containing Rh-positive test cells; if after incubating for from 1 to 2 hr at 37°C no agglutination occurs, Rho-blocking antibodies are assumed to be present in the patient's serum.
(05 Mar 2000)
spermatogenesis-blocking agents Chemical substances which inhibit the process of spermatozoa formation at either the first stage, in which spermatogonia develop into spermatocytes and then into spermatids, or the second stage, in which spermatids transform into spermatozoa.
(12 Dec 1998)
neuromuscular blocking agents Drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. They can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarising agents) or noncompetitive, depolarising agents (neuromuscular depolarising agents). Both prevent acetylcholine from triggering the muscle contraction and they are used as anaesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.
(12 Dec 1998)
adrenergic <neurology, physiology> Refers to neurons that use catecholamines as neurotransmitters at a synapse when a nerve impulse passes i.e. The sympathetic fibres.
Also refers to neurones that are activated by, characteristic of or secreting adrenaline (adrenaline) or substances with similar activity.
(15 Jan 1998)
adrenergic agents Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters.
(12 Dec 1998)
adrenergic agonists Drugs that bind to and activate adrenergic receptors.
(12 Dec 1998)
adrenergic alpha-agonists Drugs that selectively bind to and activate alpha adrenergic receptors.
(12 Dec 1998)
adrenergic alpha-antagonists Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
(12 Dec 1998)
adrenergic amine An agent that evokes responses similar to those produced by adrenergic nerve activity (e.g., epinephrine, ephedrine, isoproterenol).
Synonym: adrenergic amine, adrenomimetic amine, sympathetic amine.
(05 Mar 2000)
adrenergic antagonists Drugs that bind to but do not activate adrenergic receptors. Adrenergic antagonists block the actions of the endogenous adrenergic transmitters epinephrine and norepinephrine.
(12 Dec 1998)
adrenergic beta-agonists Drugs that selectively bind to and activate beta-adrenergic receptors.
(12 Dec 1998)
adrenergic beta-antagonists Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.
(12 Dec 1998)
adrenergic blockade Selective inhibition by a drug of the responses of effector cells to adrenergic sympathetic nerve impulses (sympatholytic) and to epinephrine and related amines (adrenolytic).
(05 Mar 2000)
adrenergic bronchodilator <pharmacology> A medication that acts to dilate (enlarge) the lumen of the airway to allow the unrestricted passage of air. These medications are commonly given to those with asthma who manifest wheezing.
Examples include: theophylline, aminophylline, adrenaline, Alupent, metaproterenol, isoproterenol, Ventolin, Proventil, bitolterol, salmeterol, pirbuterol and albuterol.
See: wheezing.
(27 Sep 1997)
adrenergic fibres Nerve fibres liberating catecholamines at a synapse after an impulse.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • estate agent
    ºÎµ¿»ê°ü¸®ÀÎ;Áß°³¾÷ÀÚ
  • fiscal agent
    À繫 ´ë¸® ±â°ü;À繫 ´ë¸®ÀÎ
  • forwarding agent
    ¿î¼Û¾÷ÀÚ
  • free agent
    ÀÚÁÖÀûÀÎ ÇàÀ§ÀÚ;ÀÚÀ¯°è¾à ¼±¼ö )
  • general agent
    ÃѴ븮ÀÎ
  • house agent
    º¹´ö¹æ;°¡¿Á ¸Å¸Å ¼Ò°³¾÷ÀÚ
  • inquiry agent
    (¿µ)»ç½Ç ŽÁ¤
  • insurance agent
    º¸Çè´ë¸®Á¡
  • land agent
    ÅäÁö ¸Å¸Å Áß°³¾÷ÀÚ;ÅäÁö °ü¸®ÀÎ
  • nerve agent
    (±º¿ëÀÇ)½Å°æ°è¿¡ ÀÛ¿ëÇÏ´Â ¹°Áú;½Å°æ°¡½º(µî)
  • parliamentary agent
    Á¤´çÀÇ ÀÇȸ ´ëº¯ÀÎ
  • press agent
    º¸µµ¿ø;¼±Àü¿ø
  • publicity agent
    ±¤°í ´ë¸®¾÷ÀÚ
  • purchasing agent
    ±¸¸Å ´ã´ç
  • reducing agent
    ȯ¿øÁ¦
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á